Metsera, Inc.
Metsera, Inc. (MTSR): 6 pipeline candidates · ~17 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
16.6 months
D/E 0.68 · 0% dilution
Lead: Approved
6 candidates
N/A
N/A
A transparent, data-derived signal for Metsera, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.4B
Cash
$448.5M
Quarterly Burn
$81.7M
Runway
16.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| company's monthlymet-097iandmet-233icombination | Approved |
| company's monthlymet-097iandmet-233icombination | Approved |
| met-097i | Phase 2 |
| met-097o | Preclinical |
| met-224o | Preclinical |
| met-233i | Phase 1 |
Frequently asked questions
How many drug candidates are in Metsera, Inc.'s pipeline?
Metsera, Inc. (MTSR) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Metsera, Inc.'s lead drug candidate?
Metsera, Inc.'s most advanced tracked candidate is company's monthlymet-097iandmet-233icombination (Approved).
What is Metsera, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Metsera, Inc. has approximately 16.6 months of cash runway.
What is Metsera, Inc.'s market capitalization?
Metsera, Inc.'s market capitalization is approximately $7.4B.
Who is the CEO of Metsera, Inc.?
Mr. Christopher Whitten Bernard is the chief executive officer of Metsera, Inc. (MTSR).
Get the full picture on Metsera, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.